🇺🇸·6d agoResearch
NIH award: FDA Phase 1 Development of a Novel Nonopioid Cell and Tissue Permeable Peptide Therapeutic for Epigenetic Reprogramming of Neuropathic Pain
Recipient: ALCAMENA STEM CELL THERAPEUTICS, LLC. Award amount: 1500000.
Publisher
N
NIH RePORTER
USA
This page provides a limited summary, publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- NIH RePORTER
- Region
- USA
- Scope
- Research
- Published
- September 4, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Recipient: ALCAMENA STEM CELL THERAPEUTICS, LLC. Award amount: 1500000.
Source route
Continue on reporter.nih.gov
Leave the platform to read the original full article on the publisher site.
Source: NIH RePORTER
Scope: Research
Related coverage
More related coverage
McGill Faculty of Medicine News/9h ago
PGME Orientation 2026: The day in photos
McGill Faculty of Medicine News/9h ago
Orientation welcomes new students to the Ingram School of Nursing
McGill Faculty of Medicine News/9h ago
SPOT students ready for the new academic year
McGill Faculty of Medicine News/9h ago